Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.13/43333

OpenURL Link
Title
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Author/Creator
Dowsett, Mitch;  Allred, Craig;  Bishop, Hugh;  Ellis, Ian;  Larsimont, Danis;  Sasano, Hironobu;  Carder, Pauline;  Cussac, Antonio L.;  Knox, Fiona;  Speirs, Valerie;  Forbes, John;  Buzdar, Aman;  Knox, Jill;  Quinn, Emma;  Salter, Janine;  Wale, Chris;  Cuzick, Jack;  Houghton, Joan;  Williams, Norman;  Mallon, Elizabeth
Institution
The University of Newcastle. Faculty of Health, School of Medicine and Public Health
Description
Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-receptor (PgR) expression and human epidermal growth factor 2 (HER-2) status with time to recurrence (TTR) in postmenopausal women with hormone receptor–positive primary breast cancer treated with anastrozole or tamoxifen as adjuvant therapy. Patients and Methods: Formalin-fixed, paraffin-embedded tumor blocks were retrospectively collected from patients in the monotherapy arms of the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial and centrally tested for ER, PgR and HER-2. ER and PgR were scored using continuous scales and HER-2 was scored as 0 to 3+ with 2+ cases being analyzed by fluorescence in situ hybridization. Results: Blocks were collected from 2,006 of 5,880 eligible patients. Tissue was assessable and ER and/or PgR positivity confirmed centrally in 1,782 cases. In these, TTR was longer for anastrozole than for tamoxifen by a similar extent to that in the overall trial. None of the three biomarkers identified a set of patients with differential benefit from anastrozole over tamoxifen. Patients with low ER, low PgR, and high HER-2 expression had a poorer prognosis with either drug. Only 2.6% of patients in the highest quartile of PgR experienced recurrence after 5 years, compared with 13.2% in the lowest quartile. Conclusion: Quantitative expression of ER and PgR and HER-2 status did not identify patients with differential relative benefit from anastrozole over tamoxifen: TTR was longer for anastrozole than for tamoxifen in all molecular subgroups. Low ER or PgR or high HER-2 expression are associated with a high risk of recurrence with either anastrozole or tamoxifen.
Relation
Journal of Clinical Oncology Vol. 26, Issue 7, p. 1059-1065
Publisher Link
http://dx.doi.org/10.1200/JCO.2007.12.9437
Date
2008
Publisher
American Society of Clinical Oncology
Keyword(s)
estrogen-receptor;  progesterone-receptor;  human epidermal growth factor 2 (HER-2);  time to recurrence;  postmenopausal women;  tamoxifen;  anastrozole
Resource Type
journal article
Identifier
http://hdl.handle.net/1959.13/43333
Identifier
ISSN:0732-183X
Reviewed
Reviewed
19 Visitors 20 Hits 0 Downloads
Save/E-mail Citation
Citation Format
E-mail Address
Subject
"Journal of Clinical Oncology"
 
OR